# Linoleic acid addition prevents Staphylococcus aureus biofilm formation on PMMA bone cement

**Authors:** Linglu Hong, Karin Hjort, Dan I. Andersson, Cecilia Persson

PMC · DOI: 10.1016/j.bioflm.2025.100311 · Biofilm · 2025-08-07

## TL;DR

Adding linoleic acid to bone cement can prevent Staphylococcus aureus biofilms, including antibiotic-resistant strains, and may work better when combined with gentamicin.

## Contribution

Linoleic acid in bone cement inhibits S. aureus biofilms, including gentamicin-resistant strains, and synergizes with gentamicin.

## Key findings

- LA-loaded bone cement significantly inhibits Staphylococcus aureus biofilm formation.
- LA combined with gentamicin broadens antibacterial spectrum and increases antibiotic efficacy.
- Released MMA from bone cement does not significantly affect bacterial growth.

## Abstract

Acrylic bone cement is widely used in vertebroplasty to treat osteoporosis-induced vertebral compression fractures. However, infection after vertebroplasty is problematic and previous work has suggested loading the bone cement with an antibiotic for prophylaxis. Linoleic acid (LA) has been investigated as a promising additive to improve the mechanical properties of bone cement for vertebroplasty, but LA could potentially also have an antibacterial effect. In this study, we evaluated the antibacterial properties of LA-loaded bone cement by comparing its antibiofilm properties with that of original bone cement through quantification of bacterial growth using viable cell count and scanning electron microscopy. The released monomer (MMA) concentration and the monomer minimum inhibitory concentration were determined to clarify the monomer's potential role in inhibiting bacterial growth. The LA release profile was measured, and a checkerboard assay was done to determine any synergistic effects of LA and the commonly used antibiotic gentamicin. Results show that LA-loaded bone cement could significantly inhibit Staphylococcus aureus biofilm formation, including gentamicin-resistant strains, but with limited effect on Escherichia coli. Furthermore, the released MMA did not have a significant influence on bacterial growth. The checkerboard assay results show that the LA and gentamicin combination could broaden the antibacterial spectrum and increase gentamicin efficacy. In conclusion, LA merits further investigation as an antibacterial agent in bone cement, alone or in combination with antibiotics.

## Linked entities

- **Chemicals:** linoleic acid (PubChem CID 5280450), gentamicin (PubChem CID 3467)
- **Diseases:** osteoporosis (MONDO:0005298)
- **Species:** Staphylococcus aureus (taxon 1280), Escherichia coli (taxon 562)

## Full-text entities

- **Diseases:** vertebral compression fractures (MESH:D050815), infection (MESH:D007239), osteoporosis (MESH:D010024)
- **Chemicals:** PMMA (MESH:D019904), LA (MESH:D019787), gentamicin (MESH:D005839), MMA (-)
- **Species:** Staphylococcus aureus (species) [taxon 1280], Escherichia coli (E. coli, species) [taxon 562]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12357060/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12357060/full.md

## References

49 references — full list in the complete paper: https://tomesphere.com/paper/PMC12357060/full.md

---
Source: https://tomesphere.com/paper/PMC12357060